Gyre Therapeutics, Inc.
GYRE Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$5.85
KIRA · Stoqly’s AI analyst, in plain words
- Gyre Therapeutics, Inc. had $117M of revenue in fiscal 2025, up 10.2% on the year before. Over five years, revenue changed +41.0% a year on average.
- Its operating margin was 9.9%, down 5.4 pts: of every 100 in sales, about 10 is left after running the business.
- Gyre Therapeutics, Inc. made $9.9M of net profit in fiscal 2025.
- Free cash flow was −$0.2M in fiscal 2025, −0.2% of revenue.
Market cap
$589M
P/E
—
Revenue
$117M
Net income
$9.9M
Free cash flow
−$0.2M
Operating margin
9.9%
Gyre Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+10.2%
Yes. Sales grew 10.2% last year.
Does it make a profit?
8.5%
A little. It keeps 8.5% of every sale as profit.
Does profit turn into cash?
−0.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Gyre Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 13, 2026
- Legal name
- GYRE THERAPEUTICS, INC.
- CIK
- 0001124105
Gyre Therapeutics, Inc. · GYRE
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $7.3M | $102M | $113M | $106M | $117M |
| Revenue growth | −65.0% | 1,294.0% | 10.9% | −6.8% | 10.2% |
| Net interest income | — | $0.7M | $1.0M | $1.5M | $1.7M |
| Gross margin | — | 95.3% | 95.9% | 96.3% | 95.4% |
| Operating margin | −1,197.8% | 9.0% | −59.3% | 15.3% | 9.9% |
| Net income | −$87.9M | $4.3M | −$85.5M | $17.9M | $9.9M |
| Net margin | −1,198.3% | 4.2% | −75.3% | 16.9% | 8.5% |
| Diluted EPS | −$2.87 | $0.03 | −$1.41 | $0.05 | $0.02 |
| Cash | |||||
| Cash from operations | −$83.8M | $10.7M | $25.9M | −$3.6M | $1.0M |
| Capital expenditure | $0.8M | $5.0M | $8.5M | $2.3M | $1.2M |
| Free cash flow | −$84.6M | $5.7M | $17.4M | −$6.0M | −$0.2M |
| FCF margin | −1,152.8% | 5.6% | 15.3% | −5.6% | −0.2% |
| Dividends paid | — | $45.0M | — | — | — |
| Share count change | 59.8% | 147.0% | −13.0% | 55.4% | 0.9% |
| Debt and strength | |||||
| Cash and short-term investments | $46.9M | $25.2M | $33.5M | $26.7M | $64.5M |
| Shareholders' equity | $41.1M | $42.5M | −$15.8M | $63.3M | $62.5M |
| Current ratio | 3.6x | 4.1x | 2.9x | 3.3x | 6.3x |
| Returns and quality | |||||
| Return on equity | −150.1% | 10.3% | −640.4% | 75.4% | 15.7% |
| Return on tangible equity | −214.0% | 5.5% | — | 19.2% | 8.7% |
| Piotroski F-score | 1 | 6 | 4 | 4 | 3 |
| Altman Z'' | −26.8 | 7.5 | −4.6 | 3.8 | 4.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.0M
2 insiders
Of sales under plans
9%
$0.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Gyre Therapeutics, Inc. · GYRE
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $5.85 a share, the company is worth $589M.
Source: SEC EDGAR XBRL filings (CIK 0001124105). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.